1. Prophylaxis for hereditary angioedema with lanadelumab and C1 Inhibitors: effectiveness and value : final evidence report Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, November 25, 2018 Subject(s): Angioedemas, Hereditary -- drug therapyAngioedemas, Hereditary -- prevention & controlAntibodies, Monoclonal, Humanized -- therapeutic useComplement C1 Inhibitor Protein -- therapeutic useKallikreins -- antagonists & inhibitorsAntibodies, Monoclonal, Humanized -- adverse effectsAntibodies, Monoclonal, Humanized -- economicsComplement C1 Inhibitor Protein -- adverse effectsComplement C1 Inhibitor Protein -- economicsCost-Benefit AnalysisRandomized Controlled Trials as TopicTreatment OutcomeHumansUnited States